Search Menu
The Institute of Medical Sciences

Dr Elaina Collie-Duguid

Dr Elaina Collie-Duguid
Dr Elaina Collie-Duguid
Dr Elaina Collie-Duguid

BSc (Hons) (First Class, Brisbane, Australia, 1990), PhD (Aberdeen, 1997)

Manager, Centre for Genome Enabled Biology & Medicine

About
Email Address
e.collie-duguid@abdn.ac.uk
Telephone Number
+44 (0)1224 437958
Office Address

School of Medicine, Medical Sciences and Nutrition. Room 4.015. Polwarth Bulding. Foresterhill. Aberdeen. AB25 2ZD

and

Centre for Genome Enabled Biology and Medicine. Room G17. 23 St Machar Drive. Old Aberdeen. Aberdeen. AB24 3RY.

 

School/Department
School of Medicine, Medical Sciences and Nutrition

Biography

Elaina Collie-Duguid was awarded a first class BSc (Hons) degree in molecular biology from the University of Queensland, Brisbane, Australia in 1990. Her time as a research assistant at the Centre for Molecular Biology and Biotechnology (currently The Institute of Molecular Bioscience), University of Queensland, was followed by a period of international travel, culminating in a move to Aberdeen in 1993 to begin a PhD in molecular and cellular biology at the Rowett Research Institute. In 1996, Dr Collie-Duguid took up post as a post-doctoral scientist in the Department of Medicine and Therapeutics at the University of Aberdeen and she now heads a Cancer Medicine research group with a particular focus on breast cancer within the Cancer Biomedicine programme.

Dr Collie-Duguid manages the Centre for Genome Enabled Biology and Medicine (CGEBM) at the University of Aberdeen. CGEBM provides strategic direction and coordinated management of the University of Aberdeen’s genomics facilities and facilitates genomics enabled interdisciplinary research by provision of specialised expertise, infrastructure, training, a focal point for collaboration and information exchange and genomics services to the research community. CGEBM provides specialist services in next generation sequencing (NGS), microarrays, bioinformatics and biostatistics. CGEBM helps to drive genome focused research forward by developing and exploiting modern genomic technologies to accelerate discovery of novel approaches to improve human health, the environment and agriculture within the diverse programmes of applied translational, clinical, biomedical and biological research at the University of Aberdeen.

 

 

External Memberships

Scientific Member of the Experimental and Translational Medicine Research Committee of the Chief Scientist Office, 2009-2014

Scientific Member of the Biomedical and Therapeutics Research Committee of the Chief Scientist Office, 2005-2009.

Research

Research Overview

Dr Collie-Duguid's research interest is to understand the molecular and cellular mechanisms controlling tumorigenesis, survival of cancer patients and chemoresistance in solid tumours, with a particular focus on breast cancers.  Biomarker discovery for prediction of clinical outcomes, including response to therapy; and novel drug target identification for drug development are key elements of her translational research programme. Dr Collie-Duguid has an interest in using genomic tools to understand human disease and important biological processes.

Teaching

Teaching Responsibilities

Dr Collie-Duguid teaches on level 5 courses MB5021 Bioinformatics, MT5003 Drug Metabolism and Toxicology, and MT5515 Research Methods, level 4 PA4302 Molecular Toxicology, level 3 PA3802 Mechanisms of Disease and Principles of Chemotherapy and Intercalated BSc MB ChB teaching in Genetic variation and Bioinformatics, and provides research project supervision to level 5 MSc students in the field of genomics.  

Publications

Page 2 of 3 Results 26 to 50 of 64

  • Growth hormone in vascular pathology: Neovascularisation and expression of receptors is associated with cellular proliferation

    Guo, X., Goessl, E., Jin, G., Collie-Duguid, E. S., Cassidy, J., Wang, W., O'Brien, V.
    Anticancer Research, vol. 28, no. 2B, pp. 1439
    Contributions to Journals: Articles

  • Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro

    Smith, T. A. D., Sharma, R. I., Wang, W. G., Welch, A., Schweiger, L. F., Collie-Duguid, E. S. R.
    Nuclear Medicine and Biology, vol. 34, no. 8, pp. 955-960
    Contributions to Journals: Articles

  • Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks

    Wang, W., McLeod, H. L., Cassidy, J., Collie-Duguid, E. S. R.
    Cancer Chemotherapy and Pharmacology, vol. 59, no. 6, pp. 839-845
    Contributions to Journals: Articles

  • Cancer Therapy Prognosis and Target

    Collie-Duguid, E. S. R., Petty, R. D., Kerr, K.
    Patents: Patents

  • Pregnane X Receptor Activators Inhibit Human Hepatic Stellate Cell Trans-Differentiation in Vitro

    Haughton, E., Tucker, S. J., Marek, C., Durward, E., Leel, V. H. M. D., Bascal, Z., Monaghan, T., Koruth, M., Collie-Duguid, E. S. R., Mann, D. A., Trim, J. E., Wright, M. C.
    Gastroenterology, vol. 131, no. 1, pp. 194-209
    Contributions to Journals: Articles

  • Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer

    Petty, R. D., Kerr, K., Murray, G. I., Nicolson, M., Rooney, P. H., Bissett, D., Collie-Duguid, E. S. R.
    Journal of Clinical Oncology, vol. 24, no. 11, pp. 1729-1744
    Contributions to Journals: Articles

  • The Rectal Adenocarcinoma Transcriptome Reveals a Novel Prognostic Biomarker and Candidate Novel Targets for Neoadjuvant Therapy (Aberdeen Microarray in Rectal Cancer Study-1; AMRECS-1)

    Collie-Duguid, E. S. R., Petty, R. D., Murray, G. I., MacDonald, G., Loudon, M., McKinley, A., O'Kelly, T., Binnie, N., Aly, E., Samuel, L.
    Colorectal Disease, vol. 8, no. S2
    Contributions to Journals: Articles

  • Gene expression profiling of clinical response in rectal adenocarcinomas reveals novel predictive biomarkers and therapeutic targets.

    Petty, R. D., Samuel, L., Murray, G. I., Loudon, M., O'Kelly, T. J., McKinley, A., MacDonald, G., Collie-Duguid, E. S. R.
    Contributions to Conferences: Abstracts

  • Global gene expression profiling of clinical response to radiotherapy and chemoradiotherapy in rectal adenocarcinoma reveals distinct and common molecular mechanisms of action.

    Petty, R. D., Samuel, L., Murray, G. I., MacDonald, G., Loudon, M., McKinley, A., O'Kelly, T. J., Collie-Duguid, E. S. R.
    Contributions to Conferences: Abstracts

  • Identification of the lysosomal programmed cell death (PCD) pathway as a critical determinant of clinical response in Non-Small Cell Lung Cancer (NSCLC).

    Petty, R. D., Kerr, K., Nicolson, M. C., Murray, G. I., Rooney, P. H., Bissett, D., Collie-Duguid, E. S. R.
    Lung Cancer, vol. 49, no. S141-142
    Contributions to Journals: Articles

  • Putative Novel Mechanisms Of Tomudex Resistance And Insight Into TS-Independent 5-Flurouracil Resistance Networks.

    Collie-Duguid, E. S. R., Cao, L., Cassidy, J., Wang, W.
    Contributions to Conferences: Abstracts

  • Rectal adenocarcinoma transcriptome profiles reveal distinct molecular effects of radiotherapy and chemoradiotherapy (Aberdeen Microarray in Rectal Cancer Study-1; AMRECS-1).

    Collie-Duguid, E. S. R., Petty, R. D., Murray, G. I., MacDonald, G., Loudon, M., McKinley, A., O'Kelly, T. J., Binnie, N., Aly, E., Samuel, L.
    Contributions to Conferences: Abstracts

  • Role of CD200 in tolerance induction: gene expression profiling of lymphoid tissues in response to intranasal antigen.

    Minas, K., Dawson, R., Collie-Duguid, E. S. R., Liversidge, J. M.
    Immunology, vol. 116, no. 13
    Contributions to Journals: Articles

  • Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells

    Wang, W., Cassidy, J., O'Brien, V., Ryan, K. M., Collie-Duguid, E. S. R.
    Cancer Research, vol. 64, pp. 8167-8176
    Contributions to Journals: Articles

  • Global profiling of molecular mechanisms of 5-fluorouracil, resistance in human cancer cells.

    Wang, W., Cassidy, J., Collie-Duguid, E. S. R.
    British Journal of Cancer, vol. 91, no. S1
    Contributions to Journals: Articles

  • Molecular mechanisms of platinum (Pt) based chemotherapy in non-small cell lung cancer patients (NSCLC) using microarrays

    Petty, R. D., Murray, G. I., Kerr, K., Nicolson, M. C., Bissett, D., Collie-Duguid, E. S. R.
    British Journal of Cancer, vol. 91, no. Supplement 1, pp. S14-S14
    Contributions to Journals: Abstracts

  • A molecular profile that predicts response to platinum based chemotherapy in non-small cell lung cancer (NSCLC) patients

    Petty, R. D., Murray, G. I., Kerr, K., Nicolson, M. C., Bissett, D., Collie-Duguid, E. S. R.
    British Cancer Research Meeting 2004, pp. S14-S14
    Contributions to Journals: Abstracts

  • Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application

    Petty, R. D., Nicolson, M. C., Kerr, K. M., Collie-Duguid, E., Murray, G. I.
    Clinical Cancer Research, vol. 10, no. 10, pp. 3237-3248
    Contributions to Journals: Articles

  • Global analysis of molecular genetic mechanisms in anti-cancer drug chemoresistance

    Wang, W., Collie-Duguid, E. S. R., Cassidy, J.
    Contributions to Conferences: Abstracts

  • Microarrays identify prognostic profiles in colon cancer patients and potential mechanisms of 5FU chemoresistance

    Collie-Duguid, E. S. R., Murray, G. I., Stewart, D. L., Bissett, D., Cassidy, J., Samuel, L.
    British Journal of Cancer, vol. 91, pp. S12-S12
    Contributions to Journals: Articles

  • Molecular profiling identifies novel cell death pathways involved in Non-Small Cell Lung Cancer (NSCLC) chemoresistance and allows prediction of response.

    Petty, R. D., Murray, G. I., Kerr, K., Nicolson, M. C., Bissett, D., Collie-Duguid, E. S. R.
    Contributions to Conferences: Abstracts

  • Molecular profiling of response to platinum based therapy in non-small cell lung cancer (NSCLC) patients.

    Petty, R. D., Murray, G. I., Kerr, K., Nicolson, M. C., Bissett, D., Collie-Duguid, E. S. R.
    Journal of Clinical Oncology, vol. 22, no. 14, pp. 153S-2104
    Contributions to Journals: Articles

  • Molecular signatures for prognosis prediction in colon cancer patients

    Collie-Duguid, E. S. R., Murray, G. I., Stewart, D. L., Cassidy, J., Samuel, L.
    Contributions to Conferences: Abstracts

  • Gene expression profiling of apoptosis and cell cycle control in Dukes’ C colon tumours.

    Collie-Duguid, E. S. R., Stewart, D. L., Cassidy, J., Murray, G. I.
    British Journal of Cancer, vol. 88, no. S1
    Contributions to Journals: Articles

  • Molecular mechanisms of cytotoxicity and pathogenesis in non-small cell lung cancer (NSCLC) using gene expression profiling.

    Petty, R. D., Nicolson, M. C., Kerr, K., Murray, G. I., Collie-Duguid, E. S. R.
    British Journal of Cancer, vol. 88, no. S1
    Contributions to Journals: Articles
Show 10 | 25 | 50 | 100 results per page

Refine

Chapters in Books, Reports and Conference Proceedings

Contributions to Conferences

Contributions to Journals

Contributions to Specialist Publications

Patents

Update